Immune checkpoint inhibitor use in antisynthetase syndrome

Asia-Pacific Journal of Clinical Oncology
David MackintoshJane Basham

Abstract

We report on the unique case of a patient with antisynthetase syndrome and metastatic non-small cell lung cancer undergoing therapy with the PD-1 checkpoint inhibitor, nivolumab. Despite adequate autoimmune disease control over a period of 12 months, the patient rapidly experienced a flare of interstitial lung disease following initial nivolumab administration, which ultimately proved fatal. The use of immune checkpoint inhibitors in patients with autoimmune disease is becoming more commonplace, however this is the first reported case of the use of these agents in a patient with antisynthetase syndrome. Additionally, the patient's initial clinical presentation with antisynthetase syndrome and simultaneous primary lung cancer, a rare association of which there are few case reports, makes this case interesting and unusual.

References

Mar 3, 2015·Journal of Clinical Apheresis·Bolanle A OmotosoRasheed A Balogun
Oct 3, 2015·Clinical Reviews in Allergy & Immunology·Eleni Tiniakou, Andrew L Mammen
Sep 7, 2016·Clinical Pulmonary Medicine·Leah J WittMary E Strek
Oct 1, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A M MenziesG V Long
Jan 15, 2018·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·François-Xavier DanlosOlivier Lambotte
May 11, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Giulia C LeonardiMark M Awad

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.